Visualization of Ranger Drug-Coated Balloon
RANGER™ DRUG-COATED BALLOON

Delivering above
and beyond

Vascular Surgery / Drug-Eluting Therapies / Ranger DCB / Ranger DCB Technology
 
View of medical professional's back of head wearing a surgical mask

NEXT-GENERATION TECHNOLOGY

Innovation for effortless deliverability.

Ranger™ Drug-Coated Balloon is built on the physician preferred Sterling™ 0.014”/0.018" balloon platform1 with the lowest tip entry profile of any SFA DCB2 and highly efficient drug transfer into the tissue. Ranger DCB delivers like nothing else.

 

The Lowest Tip Entry Profile of Any SFA DCB2

Ranger DCB's low profile and tapered tip enables a smooth delivery with excellent trackability and navigation through alternative access3 sites.

 

Ranger Drug-Coated Balloon from the side.


Efficient Drug Transfer

TransPax™ (citrate ester + low dose paclitaxel) is a next-generation coating that enables highly efficient drug transfer into the lesion.
Infographic showing TransPax is lipophilic and TransPax is hydrophobic.

 

Ranger DCB Product Details

Ranger DCB has a comprehensive matrix and is compatible with pedal access3

Ranger DCB matrix of stent sizes
3. Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Ranger diameters ≤6mm, testing done with Terumo GLIDESHEATH SLENDER™ 5F.

 

Proprietary Loading Tool

Serves as the balloon and drug protector to help prevent drug loss during insertion and limit a physician’s exposure to the drug.
Illustration of balloon and drug protected during loading device
1. DRG Data, CY 2020, 0.018" PTA Balloons.
2. Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Measurements taken from 6 x 120 devices for Ranger DCB, Lutonix™ 035 DCB, IN.PACT Admiral DCB and Stellarex™ 035 DCB. Lutonix 018 DCB measurements taken from 6 x 150 devices.
3. Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Ranger diameters ≤6mm, testing done with Terumo GLIDESHEATH SLENDER™ 5F.
Legs and feet of patient sitting on bed with hands on lap.

RESTENOSIS REPLACEMENT PROGRAM

Standing together.

The Bold Step Program is a statement of our confidence in the efficacy of our drug-eluting products. The program offers an Eluvia DES or Ranger DCB at no additional charge if a patient requires reintervention within the first year due to restenosis. 
Background image of surgical area and healthcare providers' hands

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Background image of healthcare providers' hands using medical equipment.

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

take the fight to pad
Top